Potential value of dual-time-point 18F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: A systematic review and meta-analysis

Nuclear Medicine Communications

Volumn 33, Issue 10, 2012, Pages 1011-1018

  Lin, Yu Yi ^a   Chen, Jin Hua ^b   Ding, Hueisch Jy ^d   Liang, Ji An ^b,c   Yeh, Jun Jun ^c,e,f   Kao, Chia Hung ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^f CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

18F fluorodeoxyglucose; dual time point imaging; meta analysis; positron emission tomography; pulmonary nodules

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BENIGN TUMOR; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DUAL TIME POINT IMAGING; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NODULE; LUNG TUMOR; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE TIME POINT IMAGING; SYSTEMATIC REVIEW; TIME; TUMOR DIAGNOSIS;

DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 84865791345     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835710d6     Document Type: Review

References (37)

1. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490. (Pubitemid 23216276)
2. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Chest 1996; 109:982-988.
3. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziè re B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25: 317-322. (Pubitemid 28219093)
4. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417. (Pubitemid 32852620)
5. Zhang H, Tian M, Oriuchi N, Higuchi T, Tanada S, Endo K. Detection of lung cancer with positron coincidence gamma camera using fluorodeoxyglucose in comparison with dedicated PET. Eur J Radiol 2003; 47:199-205. (Pubitemid 36970080)
6. Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T, et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999; 40:566-573. (Pubitemid 29171797)
7. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47:885-895. (Pubitemid 46768453)
8. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, Wahl RL. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998; 39:1302-1305. (Pubitemid 28326172)
9. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3:25.
10. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875. (Pubitemid 34747808)
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
12. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005; 9:1-113, iii.
13. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-1573. (Pubitemid 34746063)
14. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21:1525-1537. (Pubitemid 34746061)
15. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med 2002; 21:1503-1511. (Pubitemid 34746059)
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558. (Pubitemid 34746062)
17. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21:1237-1256. (Pubitemid 34467232)
18. Walter SD. The partial area under the summary ROC curve. Stat Med 2005; 24:2025-2040. (Pubitemid 40895557)
19. Núñ ez R, Kalapparambath A, Varela J. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET. Rev Esp Med Nucl 2007; 26:196-207. (Pubitemid 47242181)
20. Conrad GR, Sinha P. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun 2003; 24: 1129-1137. (Pubitemid 39625398)
21. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44:540-548. (Pubitemid 39663420)
22. Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007; 32:101-105. (Pubitemid 46148389)
23. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)FFDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008; 35:246-252.
24. Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 2008; 63:756-764.
25. Kim IJ, Kim SJ, Kim YS, Lee TH, Jeong YJ. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses. Neoplasma 2009; 56: 33-39.
26. Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Dualtime point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med 2009; 23:427-435.
27. Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Cicciò C, et al. Accuracy of early and delayed FDG PET-CTand of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009; 114:890-906.
28. Chen CJ, Lee BF, Yao WJ, Cheng L,Wu PS, Chu CL, Chiu NT. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. Am J Roentgenol 2008; 191:475-479.
29. Laffon E, de Clermont H, Begueret H, Vernejoux JM, Thumerel M, Marthan R, Ducassou D. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun 2009; 30:455-461.
30. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 2010; 68:66-71.
31. Barger RL Jr, Nandalur KR. Diagnostic performance of dual-time (18)F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 2012; 19:153-158.
32. Zasadny KR,Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850. (Pubitemid 23354506)
33. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994; 35:164-167. (Pubitemid 24018461)
34. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, Alavi A. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002; 29:1639-1647.
35. WeberW, Young C, Abdel-Dayem HM, Sfakianakis G,Weir GJ, Swaney CM, et al. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999; 40:574-578. (Pubitemid 29171798)
36. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312. (Pubitemid 24243143)
37. Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging 2009; 53:9-19.